Dr. Kevin Joseph on Retatrutide: Physician's Overview Fact-Checked

This review checks his December 2024 video against the retrieved transcript and current trial evidence. His hypotheses about tolerability, low blood sugar and non-responders need to be distinguished from results that have actually been tested. The video’s current description also promotes a peptide-protocol resource and product links; those links do not validate its medical claims.

The Triple Agonist Mechanism: A Solid Explanation

"GLP-1 and GIP receptors are located in the hypothalamus, the GI tract, and pancreatic beta cells"

1:05

Joseph explains that retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors. He groups GLP-1 and GIP together and correctly identifies their locations and functions:

"GLP-1 and GIP receptors are located in the hypothalamus of the brain, in the GI tract, as well as pancreatic beta cells. This allows for their mechanism that they're most popular for — weight loss as well as glycemic control."

Joseph correctly identifies the three main locations (brain, gut, pancreas) and their functions. His explanation of the incretin effect — that these drugs help the body "recognize that signal again" in type 2 diabetics — is a clear and accurate simplification.

The Glucagon Component: Mostly Right

"Glucagon receptors are located primarily on the liver and kidney"

3:01

Joseph explains what sets retatrutide apart from semaglutide and tirzepatide — the glucagon receptor. He describes its role in blood sugar regulation, lipolysis, and brown adipose tissue activation:

"Glucagon breaks down glucose storage in the liver to bring the blood sugar up... Glucagon also plays a role in lipolysis or fat breakdown... Glucagon receptors are also located on brown adipose tissue. By acting on this pathway it increases energy expenditure and increases metabolic activity."

Glucagon’s role in hepatic glucose output is established. The proposed fat-burning and brown-fat explanations are more tentative: the trial measured a three-receptor drug, not each receptor’s contribution to human energy expenditure.

Phase 2 Results: Right Ballpark, Wrong Details

"Participants losing almost 18% of their body weight in 24 weeks"

5:19

Joseph walks through the Phase 2 trial results but mixes up a key detail — he attributes the maximum 24-week weight loss to the wrong dose:

"The largest percentage of weight loss occurring on 8 milligrams with participants losing almost 18% of their body weight in 24 weeks."

Joseph gets the 48-week headline number right (-24.2% at 12 mg) but misattributes the 24-week maximum to 8 mg instead of 12 mg. The combined 8 mg groups reached 17.3%, close to the 12 mg result of 17.5%; this is a small dose-attribution error, not a different order of effect. He also correctly notes the difference between primary (24-week) and secondary (48-week) endpoints.

Retatrutide vs Tirzepatide: Separate Trials

"Participants lost more weight in two-thirds of the time compared to tirzepatide"

6:33

Joseph compares the Phase 2 retatrutide data to the tirzepatide SURMOUNT-1 trial:

"At 48 weeks the largest percentage of weight loss was at 12 mg where individuals lost almost 24% of their starting body weight. The only other thing we can compare this to is the tirzepatide clinical trial on obesity where participants lost 21% of their starting weight but over 72 weeks."

The quoted numbers are recognizable, but they mix retatrutide’s efficacy analysis with tirzepatide’s treatment-regimen analysis, which handles discontinuation differently. SURMOUNT-1’s 15 mg efficacy result was 22.5%. Neither comparison demonstrates a faster response in a direct trial or supports a shorter course of treatment.

TRIUMPH-4 subsequently reported 28.7% under its efficacy estimand at 68 weeks in people with obesity or overweight and knee osteoarthritis. That is a separate population. TRIUMPH-5 is studying retatrutide against tirzepatide; its results will address that trial’s doses and population, not every possible patient.

The Hypoglycemia Argument: Plausible but Unproven

"Activating the glucagon receptor helps break down glycogen stores and release glucose"

7:58

Joseph argues that the glucagon component could reduce hypoglycemia risk compared to other GLP-1 medications:

"Glucagon acts in the opposite manner of insulin. Activating the glucagon receptor activates glycogen or glucose stores that are in the liver and helps break down those glycogen stores and releases that glucose into the bloodstream to help balance out your blood sugar."

Glucagon promotes hepatic glucose output, but that does not prove retatrutide is a safer alternative for a person experiencing low glucose on another medicine. That comparative benefit has not been demonstrated, especially in people using insulin or an insulin secretagogue.

"Fewer Side Effects": Not Established

"Because it's a triple agonist, it does not bind as strongly to the GLP-1 receptor"

11:16

Joseph makes a pharmacological argument that retatrutide should have fewer GI side effects because it spreads its activity across three receptors instead of concentrating it on GLP-1:

"Semaglutide has a lot more side effects than tirzepatide... and I think that has a lot to do with how strong semaglutide binds to the GLP-1 receptor. Because retatrutide is a triple agonist, it does not bind as strongly to the GLP-1 or GIP receptor, which prevents side effects."

TRIUMPH-4 does not support promising few side effects, but it also cannot establish a statistically significant tolerability difference from semaglutide or tirzepatide in separate trials. Current Wegovy and Zepbound labels report dysesthesia too. The prediction of better tolerability remains unproven; it should not be described as conclusively disproved by a cross-trial comparison.

Non-Responders: Reasonable Speculation

"Because of this extra pathway, I'm hoping retatrutide may bring hope for non-responders"

9:50

Joseph identifies a patient population he thinks could benefit most from retatrutide — non-responders to semaglutide and tirzepatide:

"Non-responders to GLP-1s are patients who are at the maximum dose — either 15 mg for tirzepatide or 2.4 mg for semaglutide — and they're not having any sort of weight loss. Because of this extra pathway that retatrutide acts on, the glucagon pathway, it may bring hope for non-responders."

The possibility of helping people with an inadequate response to another drug is a research question. Receptor count and general obesity-trial results do not establish a switching strategy, reliable rescue of non-response, or better tolerability in people who stopped another medicine.

The quoted 15 mg tirzepatide and 2.4 mg semaglutide doses reflect the obesity products available when he recorded the video. Wegovy HD 7.2 mg was approved in 2026, so 2.4 mg is no longer the highest approved semaglutide injection dose for eligible adults. His non-responder hypothesis remains distinct from an approved indication.

Frequently Asked Questions

Sources

• Novo Nordisk/FDA. Current Wegovy label.
• FDA. Current Zepbound label.
• Joseph, K. (2024). "Everything you need to know about Retatrutide, the newest GLP1 agonist." YouTube. Watch on YouTube
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Eli Lilly and Company. (2025). TRIUMPH-4 results press release. Press release
• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine (SURMOUNT-1). DOI: 10.1056/NEJMoa2206038
• Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
• Li, W., et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. DOI: 10.1038/s41421-024-00700-0